ImmunOs Therapeutics Secures Funding to Advance Cancer Trials
Recent Funding Boost for ImmunOs Therapeutics AG
ImmunOs Therapeutics AG, a pioneering biopharmaceutical company that utilizes a unique immune system modulating HLA-based technology, has successfully closed a Series C financing round, raising $11 million. This financial injection aims to further the development of innovative cancer therapies and strengthen its investor relationships.
Collaboration with Key Investors
This funding round saw significant backing from existing investors, including Gimv, Pfizer Ventures, Mission BioCapital, and BioMed Partners. New investor Double Point Ventures also joined, showcasing robust confidence in the company’s future. Notably, Steve Tregay, PhD, the Managing General Partner of Mission BioCapital, has taken a position on the Company’s Board of Directors, reflecting a strategic move to enhance governance and oversight.
Advancing Clinical Trials for IOS-1002
The funds garnered from this financing initiative will primarily support the ongoing Phase Ia dose escalation clinical trials of ImmunOs' lead candidate, IOS-1002. This groundbreaking investigational treatment is being evaluated as a monotherapy and in combination with Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab), displaying its potential in a diverse approach to battling advanced solid tumors.
Significance of IOS-1002 in Cancer Treatment
IOS-1002 is a novel, multifunctional immunotherapy agent that uniquely targets several immune checkpoints, leveraging naturally occurring human leukocyte antigens (HLA) to drive a multifaceted immune response. This innovative therapy aims to activate both innate and adaptive immune cells, potentially transforming the tumor microenvironment and enhancing the effectiveness of existing immuno-oncological treatments like KEYTRUDA. The comparative nature of these treatments is pivotal as the sector continues to evolve.
Voices of Support from Key Players
Reinhard Ambros, the Executive Chairman of ImmunOs Therapeutics, expressed enthusiasm about the closing of this financing round. He emphasized the importance of both existing and new investors in validating the company’s mission and future potential. “The funding allows us to proceed with our lead program IOS-1002 as a novel therapy, addressing significant medical needs in cancer treatment,” he stated. Other executives from participating firms echoed his sentiments, expressing their excitement about being part of ImmunOs Therapeutics' journey toward advancing cancer therapies.
About ImmunOs Therapeutics AG
ImmunOs Therapeutics AG is at the forefront of biopharmaceutical innovation, channeling its research and development through a distinctive immune system modulating technology platform. It focuses on creating first-in-class therapeutics designed to target cancer and autoimmune diseases effectively. Their principal program involves a highly specialized HLA-fusion protein that engages selective receptors in the immune system, thereby enhancing the body's capability to eliminate tumor cells, setting a foundation for future breakthroughs in personalized cancer therapies.
Company Contact Information
For further information regarding their pioneering work, you can contact ImmunOs Therapeutics AG at their headquarters in Schlieren, Switzerland. They remain dedicated to making strides in the clinical development of IOS-1002 and exploring its vast potential to improve the lives of patients grappling with cancer.
Frequently Asked Questions
What recent funding has ImmunOs Therapeutics AG secured?
ImmunOs Therapeutics AG has raised $11 million in a Series C financing round to support their clinical trials.
Who are the key investors involved in this funding round?
The funding round included contributions from Gimv, Pfizer Ventures, Mission BioCapital, BioMed Partners, and new investors like Double Point Ventures.
What is the focus of the IOS-1002 therapy?
IOS-1002 is an advanced immunotherapy aimed at treating solid tumors by targeting multiple immune checkpoints.
How does IOS-1002 work?
This therapy activates both innate and adaptive immune responses, potentially enhancing the effectiveness of existing treatments such as KEYTRUDA.
Where is ImmunOs Therapeutics AG located?
The company is based in Schlieren, Switzerland, focusing on developing innovative treatments for cancer and autoimmune diseases.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Osmose Enhances O-Calc Pro with New Functionalities and Tools
- L3Harris Advances Electronic Warfare Technology for F-16s
- Monroe Capital Fuels Growth for Point 41 in Restoration Sector
- Loop Secures $10M CAD to Revolutionize Global Banking Solutions
- ACA Group Elevates eComms Solutions with Advanced Archiving Tools
- TecEx Introduces Partner Portal to Enhance Global Tech Shipments
- RCI Banque Secures €800 Million through Fixed Rate Notes
- Electra Vehicles Prepares to Unveil Battery Innovations at Major Events
- Understanding Shareholder Voting Rights and Total Shares
- Iron Mountain to Highlight Innovations at Major Conference
Recent Articles
- Makersite and Autodesk Unite to Drive Sustainable Innovation
- Star Mountain Capital Welcomes Lloyd A. Sprung as Senior Advisor
- Constant AI Surveillance: A New Era in Policing and Society
- Recent U.S. Military Support for Taiwan: A Strategic Move
- S64 and Invesco Create Innovative Real Estate Fund Partnership
- Soma Gold Corp Welcomes Hector Melendez as New Leader
- Vermiculus Unveils Revolutionary VeriTrade Trading Platform
- Trace's Life-Changing Jackpot Win at Tusk Casino Revealed
- Delta's D-Bot Series Cobots Win Red Dot: Best of the Best 2024
- Delta's Innovative D-Bot Cobots Secure Prestigious Design Award
- South African Consumer Confidence Nears Levels of 2019 Again
- Jefferies Group Boosted by New Leadership Amidst Growth Surge
- JAKKS Pacific's Growth Prospects: Aiming for 58% Upside
- Federal Reserve Decisions: What Impacts on the Market Ahead?
- Intel's Missed Opportunity with PlayStation 6 Chip Deal
- Latest Insights on Riksbank Certificate Auction Results
- Vermiculus Unveils VeriTrade: A Game-Changer in Trading Tech
- Bullish Trends in S&P 500 Futures Signals Market Optimism
- Lindt & Spruengli's Stock Boosted by Barclays Upgrade Insights
- Navigating Inflation Pressures: Opportunities in Precious Metals
- Navigating Federal Rate Cuts: Strategies for Savvy Savers
- ImmunOs Therapeutics Secures $11 Million for Cancer Trials
- PuzzleHR Partners with Counslr for Enhanced Employee Wellness
- SC Ventures Invests in One Trading as First European Crypto Venue
- Eviden Enhances Berzelius Supercomputer's AI Capabilities
- Gcore Launches Innovative Protection for Web Apps and APIs
- Finance Leaders Face Challenges Keeping Up with E-Commerce Shifts
- Standish Management Expands Portfolio with CORE Acquisition
- Oxera Partners with Box for Enhanced Content Management
- Houlihan Lokey Strengthens European Software Expertise with Key Hire
- Wealth Growth: The Rise of Centi-Millionaires in 2024
- MacPaw Unveils Setapp Mobile Beta: A Game Changer for iPhone Apps
- Trina Storage Achieves Breakthrough with UL Verified Mark Certificate
- The Rise of Centi-Millionaires: A Deep Dive into Wealth Trends
- Cognizant Partners with ECB to Enhance Recreational Cricket
- Makersite Enhances Partnership with Autodesk for Better Design
- Celebrating Leadership Excellence at Card Group International
- Ataccama ONE: Revolutionizing Data Management with Impressive ROI
- FP Markets Triumphs with Three Awards at Forex Ceremony
- Exploring Dan Loeb's Strategic AI Investments: Key Insights
- MinervaX and Wacker Biotech Collaborate on GBS Vaccine Development
- Elon Musk Discusses Canadian Government's Starlink Plans
- Starbucks North America Sees Leadership Shake-up Amid Changes
- Palantir Technologies' Growth Potential Revealed by Analyst Insights
- OverIT Welcomes Henry Middleton as Chief Financial Officer
- Electrolux Group Names New Leader for Investor Relations
- Sunvozertinib Shows High Efficacy for Lung Cancer Patients
- Electrolux Group Welcomes New Head of Investor Relations
- Kenya Plans to Reduce Budget Deficit to 3.5% of GDP
- Kingfisher's Growth Fuels FTSE 100 Surge Amid Rate Cut Hopes